SCHEMBL5848773

SCHEMBL5848773

N[C@H](CCc1ccccc1)[C@H](O)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 8/20 0.65
METAP1 P53582 4/20 0.65
ERAP1 Q9NZ08 4/20 0.51
ANPEP P15144 3/20 0.51
ERAP2 Q6P179 3/20 0.51
GRIK1 P39086 1/20 0.49
ALPI P09923 1/20 0.48
PKM P14618 1/20 0.48
PTGS1 P23219 1/20 0.48
XIAP P98170 1/20 0.48
SLC7A5 Q01650 1/20 0.48
LAP3 P28838 3/20 0.47
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3841264 1.00 METAP2 (0.65) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL5848452 1.00 METAP2 (0.65) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL21458090 1.00 METAP2 (0.65) METAP2METAP1ERAP1ANPEPERAP2
Hydrochloric Acid SCHEMBL9369961 0.98 METAP2 (0.63) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL28123950 0.89 GRIK1 (0.58) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL5849399 0.89 GRIK1 (0.58) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL28028154 0.87 METAP2 (0.63) METAP2METAP1ERAP1ANPEPERAP2
Hydrochloric Acid SCHEMBL3840035 0.86 METAP2 (0.61) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL5287440 0.83 SLC1A3 (0.55) METAP2METAP1ERAP1ANPEPERAP2
SCHEMBL3841332 0.81 ALPI (0.62) ANPEPALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546087-A1 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS Abbott Laboratories (US) 2005-06-29 EP claimed
US-20040122098-A1 3-Amino-2-hydroxyalkanoic acids and their prodrugs ABBVIE INC. 2004-06-24 US claimed
WO-2004013085-A1 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS ABBOTT LABORATORIES (US) 2004-02-12 WO claimed
US-7030262-B2 3-Amino-2-hydroxyalkanoic acids and their prodrugs ABBOTT LABORATORIES (US) 2006-04-18 US disclosed
EP-1546087-A1 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS Abbott Laboratories (US) 2005-06-29 EP disclosed
US-20040122098-A1 3-Amino-2-hydroxyalkanoic acids and their prodrugs ABBVIE INC. 2004-06-24 US disclosed
WO-2004013085-A1 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS ABBOTT LABORATORIES (US) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122098-A1 3-Amino-2-hydroxyalkanoic acids and their prodrugs HDGF, HCAR2, HCAR3 METAP2 473/4885METAP1 248/4885ERAP1 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.